Neurocrine Biosciences, Inc. (NASDAQ: NBIX) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating.
Neurocrine Biosciences, Inc. (NBIX)
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
neurocrine.com/about-us/webcasts-presentations
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
NBIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NBIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NBIX alerts
High impacting Neurocrine Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
NBIX
News
- Congenital Adrenal Hyperplasia Landscape Research 2024: Comprehensive Insights About 8+ Pipeline Drugs Featuring Neurocrine Biosciences, Spruce Biosciences, Lundbeck, and HBM Alpha Therapeutics [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Neurocrine Biosciences' (NASDAQ:NBIX) Strong Earnings Are Of Good Quality [Yahoo! Finance]Yahoo! Finance
- Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) CapsulesPR Newswire
- Neurocrine Biosciences to Participate at Investor Conferences in NovemberPR Newswire
NBIX
Earnings
- 10/30/24 - Beat
NBIX
Sec Filings
- 11/12/24 - Form 4
- 11/7/24 - Form 4
- 11/1/24 - Form 4
- NBIX's page on the SEC website